Health Trials

About this trial

This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.

A Perometer and Sozo devise will be used to measure volume changes

Eligibility criteria

Qualifiers

Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF/HCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.

Females between 18 and 80 years of age

With a history of breast cancer

4 weeks or more post-surgery

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Perometer
  • SOZO device

Treatment groups

261 Participants
are divided into 2 treatment groups

Locations

1
Massachusetts General Hospital02115, BostonMassachusetts, United States

Sponsors and collaborators

Massachusetts General Hospital

Lead sponsor

Heinz Family Foundation

Collaborator

Source ClinicalTrials.gov